A randomized phase II study of carboplatin and etoposide with or without obatoclax in small cell lung cancer demonstrated that the addition of obatoclax showed a trend towards better overall response rates [ 31 ].
← all excerpts
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
1
—
—